Many patients with rare, fast-growing neuroendocrine tumors respond well to a combination of ipilimumab and nivolumab, according to the first peer-reviewed publication out of DART, a rare cancer clinical trial.
More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.
